U.S. FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
RIDGEFIELD, CONN. - August 1, 2014 - Boehringer Ingelheim announced today that its new COPD drug, Striverdi® Respimat® (olodaterol) Inhalation Spray, has been approved by the U.S. Food and Drug Administration (FDA). The long-term, once-daily maintenance broncholidator is designed to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The drug is delivered by a propellant-free inhaler that generates a soft, slow-moving mist. STRIVERDI RESPIMAT is not intended to treat acute cases of COPD or asthma.
“The approval of STRIVERDI RESPIMAT marks another step forward for our diverse respiratory pipeline that includes other compounds being evaluated using the Respimat® inhaler,” said Sabine Luik, MD, senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. “Boehringer Ingelheim has been a leading provider of treatments for people living with COPD for more than a decade, and we are continuing to investigate therapies that may provide additional benefits...”
Click here to read the full press release.